コンテンツへスキップ
Merck
すべての画像(1)

資料

安全性情報

D-033

Supelco

Dihydromorphine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C17H21NO3
CAS番号:
509-60-4
分子量:
287.35
EC Number:
200-659-6
MDL番号:
MFCD00190622
UNSPSCコード:
41116107
PubChem Substance ID:
329798599
NACRES:
NA.24

グレード

certified reference material

形状

liquid

特徴

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

メーカー／製品名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

濃度

1.0 mg/mL in methanol

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

forensics and toxicology

フォーマット

single component solution

輸送温度

wet ice

保管温度

−20°C

SMILES記法

O[C@@H](CC1)[C@@]2([H])[C@@]3([C@]1([H])[C@H](N(C)CC3)C4)C5=C4C=CC(O)=C5O2

InChI

1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1

InChI Key

IJVCSMSMFSCRME-KBQPJGBKSA-N

詳細

Dihydromorphine is a semisynthetic opioid analgesic sold under the trade names Paramorfan or Paramorphan for treatment of pain. Dihydromorphine is also a primary active metabolite of the analgesic opioid drug dihydrocodeine. This Snap-N-Spike® Reference Solution is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from urine drug testing and pain prescription monitoring to pharmaceutical research.

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

関連製品

製品番号
詳細
価格

M-031

Morphine-3-β-D-glucuronide solution, 1 mg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

E-052

エチルモルフィン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-01

Morphine N-oxide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-05

10-Hydroxymorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

IMPM-005-06

10-Oxomorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-003

Morphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-005

モルヒネ 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-006

Morphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-017

Morphine-D3-3-β-D-glucuronide solution, 100 μg/mL in methanol with 0.05% NaOH, ampule of 1 mL, certified reference material, Cerilliant®

M-018

Morphine-3-β-D-glucuronide solution, 100 μg/mL in methanol: water ( 50:50(v/v)), ampule of 1 mL, certified reference material, Cerilliant®

M-030

モルヒネ 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-046

Morphine-6-β-D-glucuronide solution, 1.0 mg/mL in methanol: water (2:8), ampule of 1 mL, certified reference material, Cerilliant®

M-085

Morphine-D6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-086

Morphine-D6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

M-096

Morphine-6-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

M-120

Morphine-6-β-D-glucuronide-D3 solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-006

Normorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

ピクトグラム

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

シグナルワード

Danger

危険有害性情報

H225,H301 + H311 + H331,H370

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

ターゲットの組織

Eyes

保管分類コード

3 - Flammable liquids

WGK

WGK 1

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

D-033-1ML:
D-033-CC:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

R Maggi et al.
European journal of pharmacology, 301(1-3), 169-177 (1996-04-22)
The present study showed that the glucocorticoid/progesterone antagonists, 17 beta-hydroxy-1 1 beta-(4-dimethylamino-phenyl-1)-17-(prop-1-ynyl)estra-4,9-dien+ ++-3-one (RU486) and 17 beta-hydroxy-11 beta-(4-dimethylamino-phenyl-1)-17-(propan-3-ol)estra-4,9-dien-3-o ne (ZK 98299), inhibit the binding of labeled dihydromorphine to mu-opioid receptors present on membrane preparations derived from rat and mouse brain
M Wieczorek et al.
Biochemical pharmacology, 54(2), 283-291 (1997-07-15)
The determination of the relationship between ligand affinity and bioactivity is important for the understanding of receptor function in biological systems and for drug development. Several physiological and pathophysiological functions of bradykinin (BK) are mediated via the B2 receptor. In
Anna K Przybyl et al.
The Journal of organic chemistry, 68(5), 2010-2013 (2003-03-01)
A practical method for the conversion of tetrahydrothebaine to dihydromorphine in 92% yield is described. The procedure should allow more efficient production of opium products and may be easily modified for large-scale synthesis. The conversion of codeine to (8S)-8-bromomorphide, a
M Grauert et al.
Journal of medicinal chemistry, 40(18), 2922-2930 (1997-08-29)
We have synthesized a series of stereoisomeric 6,7-benzomorphan derivatives with modified N-substituents and determined their ability to antagonize the N-methyl-D-aspartate (NMDA) receptor-channel complex in vitro and in vivo. The ability of the compounds to displace [3H]-MK-801 from the channel site
G B Stefano et al.
Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology, 113(3), 369-373 (1996-03-01)
A previous report demonstrated the presence of the newly discovered opiate alkaloid selective and opioid peptide insensitive mu3 receptor in ganglia of several invertebrate- and one vertebrate species as well as in microglial cells that had egressed from these ganglia
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）